Press release
Non-infectious Macular Edema Treatment Market is Forecast to Reach US$ 29,567.8 Million by 2034
Non-infectious Macular Edema Treatment Market
Growth opportunities in emerging economies are anticipated due to pipeline development, where the introduction of new drug candidates holds significant potential for market expansion. A robust pipeline featuring promising compounds signifies the future of therapeutic options, with advancements in clinical trials and successful drug approvals poised to profoundly impact the market.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9645
Country-wise Insights
By 2034, North America is expected to dominate the global non-infectious macular edema treatment market with a 35.5% share. Pharmaceutical companies in this region are likely to introduce patient assistance programs to enhance treatment accessibility, potentially boosting patient adherence and market growth. In the United States, projected to account for 92.1% of North America's market, the high prevalence of diabetes fuels demand for treatments targeting diabetic macular edema, a common complication of diabetes.
Category-wise Insights
The global demand for non-infectious macular edema treatment is set to rise significantly in the Anti-VEGF segment. Anti-VEGF drugs, administered via intravitreal injections, offer a non-invasive treatment option preferred by patients seeking less invasive procedures. By 2034, the Anti-VEGF segment is forecasted to capture 67.7% of the market share, driven by their effectiveness in reducing macular edema through inhibition of abnormal blood vessel growth in the retina, thereby improving vision and managing associated symptoms.
Read More: Fact.MR Report on Non-Infectious Macular Edema Treatment Market
Competitive Landscape
Key players in the non-infectious macular edema treatment market employ diverse strategies to achieve market leadership. These include fostering innovation, implementing stringent quality control measures, forming strategic partnerships, optimizing supply chain management, and advancing product and technology offerings.
Company Portfolio Highlights:
Allergan Plc: A global pharmaceutical company known for its focus on aesthetics, eye care, central nervous system, and gastroenterology. Allergan has been pivotal in ophthalmology with products like Ozurdex (dexamethasone intravitreal implant), addressing various retinal conditions including macular edema.
Amgen Inc.: A biotechnology leader specializing in innovative biologic medicines, including those for eye care.
Other prominent players in the market include Pfizer Inc., Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., Bayer AG, Valeant Pharmaceuticals Inc., Alimera Sciences Inc., and Clearside Biomedical, Inc. These companies drive competitiveness through comprehensive portfolios and continuous advancements in treatment options for non-infectious macular edema.
Segmentation of Non-infectious Macular Edema Treatment Market Research
By Drug Type :
Anti-VEGF
Corticosteroids
Immunosuppressant
Biologics
Others
By Route of Administration :
Oral
Parental
Topical
By Indication :
Non-Infectious Uveitic ME
Diabetic ME
Retinal Vein Occlusion ME
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region :
North America
Europe
East Asia
Latin America
Middle East & Africa
South Asia & Oceania
๐๐จ๐ง๐ญ๐๐๐ญ:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
๐๐๐จ๐ฎ๐ญ ๐ ๐๐๐ญ.๐๐
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-infectious Macular Edema Treatment Market is Forecast to Reach US$ 29,567.8 Million by 2034 here
News-ID: 3563402 • Views: โฆ
More Releases from Fact.MR
USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Develo โฆ
The U.S. microbiome skincare market is projected to experience rapid, data-driven growth over the next decade, driven by rising consumer awareness, ingredient innovation, and the integration of personalized diagnostics. Analysts estimate the U.S. microbiome skincare segment at approximately USD 0.13 billion in 2025, with a projected increase to USD 0.35 billion by 2035, representing a compound annual growth rate (CAGR) of 10.4%.
To access the complete data tables and in-depth insights,โฆ
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future โฆ
The U.S. lubricants market is projected to experience steady growth through 2035, driven by shifts in mobility, industrial demand, and sustainability trends. The market was valued at approximately $41.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $52 billion by 2035.
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12463
โฆ
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: K โฆ
"Demand for intermodal freight transport connecting the UK and continental Europe is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising trade volumes, decarbonization mandates, and digital logistics innovations. The intermodal market, encompassing rail, short-sea shipping, and last-mile road delivery, is expected to handle over 18 million TEUs (twenty-foot equivalent units) annually by 2035, up from 10.2 million TEUs in 2025.
To access the completeโฆ
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Fut โฆ
The United States hydroxyapatite (HAp) market is projected to experience sustained, data-driven growth from 2025 through 2035, fueled by rising clinical demand, technological innovation, and expanded applications in regenerative medicine. Market modeling indicates that U.S. consumption of hydroxyapatite will nearly double over the next decade, with strong adoption in orthopedic, dental, and advanced biomaterial sectors.
To access the complete data tables and in-depth insights, request a Discount On The Report here:โฆ
More Releases for Macular
Elevated Diabetes Prevalence Fuels Growth In The Macular Edema And Macular Degen โฆ
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
The market encompassing macular edema and macular degeneration has experienced substantial expansion recently, projected to increase from a value of $9.65 billion in 2024 to $10.33 billion in 2025, reflecting a compound annual growth rate (CAGR)โฆ
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co โฆ
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compoundโฆ
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro โฆ
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives inโฆ
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macularโฆ
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 โฆ
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84โฆ
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, โฆ
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. Theโฆ
